Direct Impact

Concepts for which Johan Silliard has direct influence:

mild asthma
aq001s compared
inhalation suspension
vaccine covid-19
sars cov-2
crossover trial
assess safety

Prominent publications by Johan Silliard

KOL-Index: 2 This is a prospective, active-controlled, randomized, open label, single-center, multiple dose, two-period crossover clinical trial to assess the efficacy, safety and pharmacokinetics of AQ001S compared to a budesonide inhalation suspension (comparator) in adults with mild asthma.Both treatments will be administered by nebulization. Detailed Description Adults patients with mild asthma (18 ...
Known for
Pharmacokinetics Endpoint | Safety Inhaled | Center Period | Assessed Prospective
KOL-Index: 2 The purpose of this double-blind, randomized, controlled study is to evaluate the efficacy, immunogenicity, reactogenicity and safety of an adjuvanted recombinant severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) trimeric spike (S)-protein subunit vaccine (SCB-2019) for the prevention of SARS-CoV-2-mediated COVID-19 in adult subjects 18 years of age and above. Detailed Description ...
Known for
Protein Subunit | Phase Adjuvanted | Severe Acute | Respiratory Syndrome

© 2022 - Key Opinion Leaders -
Key Opinion Leaders, LLC ,
2025 NW 102 Avenue, Suite 111 Doral , FL   33172